TY - JOUR
T1 - Panel Discussion - Problems in the Cancer Genomic Medicine
AU - Ishioka, Chikashi
AU - Muto, Manabu
AU - Yachida, Shinichi
AU - Shirota, Hidekazu
AU - Hirasawa, Akira
AU - Miyagawa, Kiyoshi
AU - Ashizawa, Kazuto
AU - Kinoshita, Ichiro
AU - Nishihara, Hiroshi
AU - Matsuura, Nariaki
AU - Sakurai, Akihiro
PY - 2022/9/1
Y1 - 2022/9/1
N2 - About 4 and a half years have passed since"Cancer Genome Medicine"was first mentioned in the Third Phase of the Basic Plan to Promote Cancer Control Programs that started in October 2017. Currently, cancer genomic medicine is being carried out by the cancer gene panel test, which is covered by public insurance, mainly at the 12 Cancer Genome Medicine Core Center Hospital designated nationwide by the Ministry of Health, Labor, and Welfare in Japan. Cancer genomic medicine has come to be positioned as a standard medical treatment. However, there are various challenges in operating an expert panel that professionally examines the results of the gene panel tests and reports treatment recommendations and secondary findings that suggest hereditary tumors. In addition, there is an urgent need to disseminate and educate healthcare professionals and patients about cancer genomic medicine. In this panel discussion on January 14, 2022, 10 panelists discussed how to solve these issues and the prospects for the future.
AB - About 4 and a half years have passed since"Cancer Genome Medicine"was first mentioned in the Third Phase of the Basic Plan to Promote Cancer Control Programs that started in October 2017. Currently, cancer genomic medicine is being carried out by the cancer gene panel test, which is covered by public insurance, mainly at the 12 Cancer Genome Medicine Core Center Hospital designated nationwide by the Ministry of Health, Labor, and Welfare in Japan. Cancer genomic medicine has come to be positioned as a standard medical treatment. However, there are various challenges in operating an expert panel that professionally examines the results of the gene panel tests and reports treatment recommendations and secondary findings that suggest hereditary tumors. In addition, there is an urgent need to disseminate and educate healthcare professionals and patients about cancer genomic medicine. In this panel discussion on January 14, 2022, 10 panelists discussed how to solve these issues and the prospects for the future.
UR - http://www.scopus.com/inward/record.url?scp=85138659672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138659672&partnerID=8YFLogxK
M3 - Article
C2 - 36156030
AN - SCOPUS:85138659672
SN - 0385-0684
VL - 49
SP - 1014
EP - 1017
JO - Gan to kagaku ryoho. Cancer & chemotherapy
JF - Gan to kagaku ryoho. Cancer & chemotherapy
IS - 9
ER -
